Cancer has long been considered a disease that is associated with immune tolerance. Its
connection with inflammation initially appears paradoxical. During the last decade, it has …

Cancer development and its response to therapy are regulated by inflammation, which
either promotes or suppresses tumor progression, potentially displaying opposing effects on …

One of the major challenges in achieving effective anti-cancer immunotherapy is to
counteract immunological tolerance. Most tumor-associated antigens (TAAs) are sensed as …

Dendritic cells (DCs) with robust immunosuppressive activity are commonly found in the
microenvironment of advanced solid tumors. These innate immune cells are generically …

Inducing effective anti-tumor immunity has become a major therapeutic strategy against
cancer. Dendritic cells (DC) are a heterogenous population of antigen presenting cells that …

The complexity of the tumor immunoenvironment is underscored by the emergence and
discovery of different subsets of immune effectors and regulatory cells. Tumor-induced …

Dendritic cells (DCs) are a heterogeneous group of antigen-presenting innate immune cells
that regulate adaptive immunity, including against cancer. Therefore, understanding the …

Pathogens or genotoxic agents continuously affect the human body. Acute inflammatory
reaction induced by a non-sterile or sterile environment is triggered for the efficient …

Tumor growth results from a delicate balance between intrinsic dysregulation of oncogenes,
tumor suppressor and stability genes counteracted by extrinsic defenses composed of …

A common characteristic of solid tumors is the pathological recruitment of
immunosuppressive myeloid cells, which in certain tumors includes dendritic cells (DCs) …